Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma

Nicole L.W. Van Hal, Guus A.M.S. Van Dongen, Corlinda B.M. Ten Brink, Karl Heinz Heider, Irene Rech-Weichselbraun, Gordon B. Snow, Ruud H. Brakenhoff

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In recent years, the measurement of soluble CD44 levels in the circulation of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the detection of human cancer. The high CD44v6 expression in head and neck squamous cell carcinoma (HNSCC) would enable the use of soluble CD44v6 proteins present in the circulation of HNSCC patients as a marker of disease. In the present study, we determined CD44v6 plasma levels using a domain-specific ELISA in healthy volunteers, non-cancer patients, and HNSCC patients before and after surgical removal of the tumor. A difference between the CD44v6 plasma levels of HNSCC patients and controls could not be observed. Moreover, surgical removal of the tumor did not result in a reduction of the CD44v6 plasma level in the HNSCC patients. In addition, the spectrum of soluble v6-containing CD44 proteins present in the plasma of HNSCC patients and controls was determined by immunoprecipitation experiments, but again, tumor-related isoforms could not he distinguished in patient samples. Additional experiments to unravel the biological source of these circulating proteins indicated surprisingly that the v6-containing proteins present in the circulation of healthy individuals are only released in part, if at all, by activated lymphocytes or other nucleated blood cells. Most circulating CD44v6 proteins seem to be derived from the normal epithelial cell compartments, including breast cells, colon cells, and squamous cells. Taken together, these data do not support the use of soluble CD44v6 as a tumor marker in HNSCC or any other tumor type that has developed from tissues producing soluble isoforms.

Original languageEnglish
Pages (from-to)3534-3541
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number11
Publication statusPublished - 1 Nov 1999

Cite this

Van Hal, N. L. W., Van Dongen, G. A. M. S., Ten Brink, C. B. M., Heider, K. H., Rech-Weichselbraun, I., Snow, G. B., & Brakenhoff, R. H. (1999). Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clinical Cancer Research, 5(11), 3534-3541.
Van Hal, Nicole L.W. ; Van Dongen, Guus A.M.S. ; Ten Brink, Corlinda B.M. ; Heider, Karl Heinz ; Rech-Weichselbraun, Irene ; Snow, Gordon B. ; Brakenhoff, Ruud H. / Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 11. pp. 3534-3541.
@article{4d75dc9a8a67434aa5e027f418935ff2,
title = "Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma",
abstract = "In recent years, the measurement of soluble CD44 levels in the circulation of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the detection of human cancer. The high CD44v6 expression in head and neck squamous cell carcinoma (HNSCC) would enable the use of soluble CD44v6 proteins present in the circulation of HNSCC patients as a marker of disease. In the present study, we determined CD44v6 plasma levels using a domain-specific ELISA in healthy volunteers, non-cancer patients, and HNSCC patients before and after surgical removal of the tumor. A difference between the CD44v6 plasma levels of HNSCC patients and controls could not be observed. Moreover, surgical removal of the tumor did not result in a reduction of the CD44v6 plasma level in the HNSCC patients. In addition, the spectrum of soluble v6-containing CD44 proteins present in the plasma of HNSCC patients and controls was determined by immunoprecipitation experiments, but again, tumor-related isoforms could not he distinguished in patient samples. Additional experiments to unravel the biological source of these circulating proteins indicated surprisingly that the v6-containing proteins present in the circulation of healthy individuals are only released in part, if at all, by activated lymphocytes or other nucleated blood cells. Most circulating CD44v6 proteins seem to be derived from the normal epithelial cell compartments, including breast cells, colon cells, and squamous cells. Taken together, these data do not support the use of soluble CD44v6 as a tumor marker in HNSCC or any other tumor type that has developed from tissues producing soluble isoforms.",
author = "{Van Hal}, {Nicole L.W.} and {Van Dongen}, {Guus A.M.S.} and {Ten Brink}, {Corlinda B.M.} and Heider, {Karl Heinz} and Irene Rech-Weichselbraun and Snow, {Gordon B.} and Brakenhoff, {Ruud H.}",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "5",
pages = "3534--3541",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

Van Hal, NLW, Van Dongen, GAMS, Ten Brink, CBM, Heider, KH, Rech-Weichselbraun, I, Snow, GB & Brakenhoff, RH 1999, 'Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma' Clinical Cancer Research, vol. 5, no. 11, pp. 3534-3541.

Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. / Van Hal, Nicole L.W.; Van Dongen, Guus A.M.S.; Ten Brink, Corlinda B.M.; Heider, Karl Heinz; Rech-Weichselbraun, Irene; Snow, Gordon B.; Brakenhoff, Ruud H.

In: Clinical Cancer Research, Vol. 5, No. 11, 01.11.1999, p. 3534-3541.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma

AU - Van Hal, Nicole L.W.

AU - Van Dongen, Guus A.M.S.

AU - Ten Brink, Corlinda B.M.

AU - Heider, Karl Heinz

AU - Rech-Weichselbraun, Irene

AU - Snow, Gordon B.

AU - Brakenhoff, Ruud H.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - In recent years, the measurement of soluble CD44 levels in the circulation of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the detection of human cancer. The high CD44v6 expression in head and neck squamous cell carcinoma (HNSCC) would enable the use of soluble CD44v6 proteins present in the circulation of HNSCC patients as a marker of disease. In the present study, we determined CD44v6 plasma levels using a domain-specific ELISA in healthy volunteers, non-cancer patients, and HNSCC patients before and after surgical removal of the tumor. A difference between the CD44v6 plasma levels of HNSCC patients and controls could not be observed. Moreover, surgical removal of the tumor did not result in a reduction of the CD44v6 plasma level in the HNSCC patients. In addition, the spectrum of soluble v6-containing CD44 proteins present in the plasma of HNSCC patients and controls was determined by immunoprecipitation experiments, but again, tumor-related isoforms could not he distinguished in patient samples. Additional experiments to unravel the biological source of these circulating proteins indicated surprisingly that the v6-containing proteins present in the circulation of healthy individuals are only released in part, if at all, by activated lymphocytes or other nucleated blood cells. Most circulating CD44v6 proteins seem to be derived from the normal epithelial cell compartments, including breast cells, colon cells, and squamous cells. Taken together, these data do not support the use of soluble CD44v6 as a tumor marker in HNSCC or any other tumor type that has developed from tissues producing soluble isoforms.

AB - In recent years, the measurement of soluble CD44 levels in the circulation of patients with malignant diseases has been introduced as a new and simple diagnostic tool for the detection of human cancer. The high CD44v6 expression in head and neck squamous cell carcinoma (HNSCC) would enable the use of soluble CD44v6 proteins present in the circulation of HNSCC patients as a marker of disease. In the present study, we determined CD44v6 plasma levels using a domain-specific ELISA in healthy volunteers, non-cancer patients, and HNSCC patients before and after surgical removal of the tumor. A difference between the CD44v6 plasma levels of HNSCC patients and controls could not be observed. Moreover, surgical removal of the tumor did not result in a reduction of the CD44v6 plasma level in the HNSCC patients. In addition, the spectrum of soluble v6-containing CD44 proteins present in the plasma of HNSCC patients and controls was determined by immunoprecipitation experiments, but again, tumor-related isoforms could not he distinguished in patient samples. Additional experiments to unravel the biological source of these circulating proteins indicated surprisingly that the v6-containing proteins present in the circulation of healthy individuals are only released in part, if at all, by activated lymphocytes or other nucleated blood cells. Most circulating CD44v6 proteins seem to be derived from the normal epithelial cell compartments, including breast cells, colon cells, and squamous cells. Taken together, these data do not support the use of soluble CD44v6 as a tumor marker in HNSCC or any other tumor type that has developed from tissues producing soluble isoforms.

UR - http://www.scopus.com/inward/record.url?scp=0032713934&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 3534

EP - 3541

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -

Van Hal NLW, Van Dongen GAMS, Ten Brink CBM, Heider KH, Rech-Weichselbraun I, Snow GB et al. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Clinical Cancer Research. 1999 Nov 1;5(11):3534-3541.